$CHEK at $1.16 Price Target Lowered to $5.50 at HC Wainwright
Check-Cap Ltd. (NASDAQ:CHEK) had its price objective reduced by HC Wainwright from $7.00 to $5.50 in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 433.98% from the stock’s previous close.
Other equities analysts also recently issued reports about the company. ValuEngine upgraded Check-Cap from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Check-Cap in a research note on Wednesday, September 27th. Finally, Zacks Investment Research upgraded Check-Cap from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $4.63.